Exploring Analyst Estimates for Elanco Animal Health (ELAN) Q4 Earnings, Beyond Revenue and EPS

Wall Street analysts expect Elanco Animal Health Incorporated (ELAN) to post quarterly earnings of $0.15 per share in its upcoming report, which indicates a year-over-year increase of 87.5%. Revenues are expected to be $1.01 billion, down 2.2% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.That said, let's delve into the average estimates of some Elanco Animal Health metrics that Wall Street analysts commonly model and monitor.The combined assessment of analysts suggests that 'Revenue- Total Pet Health' will likely reach $428.67 million. The estimate suggests a change of +3.1% year over year.Analysts expect 'Revenue- Total Contract Manufacturing' to come in at $9.35 million. The estimate indicates a change of +3.9% from the prior-year quarter.According to the collective judgment of analysts, 'Revenue- Total Farm Animal' should come in at $575.40 million. The estimate points to a change of -5.7% from the year-ago quarter.View all Key Company Metrics for Elanco Animal Health here>>>Shares of Elanco Animal Health have demonstrated returns of -8.8% over the past month compared to the Zacks S&P 500 composite's -0.5% change. With a Zacks Rank #4 (Sell), ELAN is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Elanco Animal Health Incorporated (ELAN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks